Breast Cancer Research and Treatment

, Volume 21, Issue 2, pp 101–109

Prognostic factors and natural history in lymph node-negative breast cancer patients

  • Rodrigo Arriagada
  • Lars Erik Rutqvist
  • Lambert Skoog
  • Hemming Johansson
  • Andrew Kramar


The prognostic significance of clinical and histological factors as well as hormone receptors was analyzed in a population of 3,064 lymph node-negative breast cancer patients operated in the Stockholm region between 1976 and 1988. None of these patients received systemic adjuvant treatment. Multivariate analysis showed that only histological tumor size, number of examined axillary lymph nodes, and progesterone receptors were independent prognostic factors in terms of recurrence-free interval. An individual risk of recurrence was calculated taking into account these three factors to discriminate between three groups of patients with a risk of less than 15%, 15–25%, and more than 25% of recurrence at 5 years. Similar results were obtained taking into account only the first two factors. The prognostic information added by the knowledge of progesterone receptors only changed the recurrence rate in approximately 3%. This study showed that conventional prognostic factors permit the identification of high risk lymph node-negative breast cancer patients. Results obtained by the use of new more sophisticated factors should be compared with those obtained analyzing strong conventional prognostic factors.

Key words

axillary lymph nodes node-negative breast cancer prognosis hormone receptors progesterone receptor tumor size multivariate analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Early Breast Cancer Trialists' Collaborative Group: Treatment of early breast cancer. Vol 1. Worldwide evidence 1985–1990. In: Oxford Medical Publications, 1990Google Scholar
  2. 2.
    Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J: The importance of histologic grade in long-term prognosis of breast cancer. A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5: 1378–1386, 1987PubMedGoogle Scholar
  3. 3.
    Joensuu H, Toikkanen S, Klemi PJ: DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 66: 331–340, 1990PubMedGoogle Scholar
  4. 4.
    Von Rosen A, Rutqvist LE, Carstensen J, Fallenius A, Skoog L, Auer G: Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content. Breast Cancer Res Treat 13: 23–32, 1989PubMedGoogle Scholar
  5. 5.
    McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. JNCI 82: 1006–1015, 1990PubMedGoogle Scholar
  6. 6.
    Wrange Ö, Nordenskjöld B, Gustafsson JA: Cytosol estradiol receptor in human mammary carcinoma. An assay based on isolectric focusing in polyacrylamide gel. Anal Biochem 85: 416–421, 1978Google Scholar
  7. 7.
    Burton KA: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem J 62: 315–322, 1956PubMedGoogle Scholar
  8. 8.
    UICC: TNM: Classification of malignant tumours. 3rd edition. Geneva, 1979Google Scholar
  9. 9.
    Arriagada R, Mouriesse H, Sarrazin D, Clark RM, Deboer G: Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and The Princess Margaret Hospital. Int J Radiat Oncol Biol Phys 11: 1751–1757, 1985PubMedGoogle Scholar
  10. 10.
    Byar DP: Analysis of survival data: Cox and Weibull models with covariates. In: Miké V, Stanley KE (eds) Statistics in Medical Research. J. Wiley, New York, 1982, pp 365–401Google Scholar
  11. 11.
    Christensen E: Multivariate survival analysis using Cox's regression model. Hepatology 7: 1346–1358, 1987PubMedGoogle Scholar
  12. 12.
    Gelman R, Gelber R, Henderson JC, Coleman CN, Harris JR: Improved methodology for analysing local and distant recurrence. J Clin Oncol 8: 548–555, 1990PubMedGoogle Scholar
  13. 13.
    Kramar A, Pejovic MH, Chassagne DA: A method of analysis taking into account competing events: application to the study of digestive complications following irradiation for cervical cancer. Stat Med 6: 785–794, 1987PubMedGoogle Scholar
  14. 14.
    Arriagada R, Rutqvist LE, Kramar A, Johansson H: Competing risks determining event-free survival in early breast cancer. Brit J Cancer (submitted)Google Scholar
  15. 15.
    Fisher B, Redmond C, Fisher ER, Caplan R, et al.: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076–1087, 1988PubMedGoogle Scholar
  16. 16.
    Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, Sarrazin D: Breast cancer, relationship between the size of the primary tumour and the probability of metastatic dissemination. Brit J Cancer 49: 709–715, 1984PubMedGoogle Scholar
  17. 17.
    Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917–2924, 1980PubMedGoogle Scholar
  18. 18.
    Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: Pathological prognostic factors in stage I (TINIMo) and stage II (TINIMo) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7: 1239–1251, 1989PubMedGoogle Scholar
  19. 19.
    Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41: 1170–1178, 1978PubMedGoogle Scholar
  20. 20.
    O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8: 2040–2046, 1990PubMedGoogle Scholar
  21. 21.
    Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989PubMedGoogle Scholar
  22. 22.
    Martin JE, Gallager HS: Mammographic diagnosis of minimal breast cancer. Cancer 28: 1519–1526, 1971PubMedGoogle Scholar
  23. 23.
    Frazier TG, Copeland AM, Gallager HS, Paulus DD, White EC: Prognosis and treatment in minimal breast cancer. Am J Surg 133: 697–701, 1977PubMedGoogle Scholar
  24. 24.
    Wilking N, Rutqvist LE, Carstensen J, Mattsson A, Skoog L, et al.: Prognosis significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncologica (in press)Google Scholar
  25. 25.
    Dewar JA, Sarrazin D, Benhamou S, Petit JY, Benhamou E, Arriagada R, Fontaine F, Castaigne D, Contesso G: Management of the axilla in conservatively treated breast cancer: 592 patients treated at the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 13: 475–481, 1987PubMedGoogle Scholar
  26. 26.
    Fisher B, Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 130: 79–88, 1970Google Scholar
  27. 27.
    McGuire WL: Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 6: 1071–1072, 1988PubMedGoogle Scholar
  28. 28.
    Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045–1053, 1990PubMedGoogle Scholar
  29. 29.
    Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N: Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47: 6126–6133, 1987PubMedGoogle Scholar
  30. 30.
    Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324: 160–168, 1991PubMedGoogle Scholar
  31. 31.
    McGuire WL: Adjuvant therapy of node-negative breast cancer (Editorial). N Engl J Med 320: 525–527, 1989PubMedGoogle Scholar
  32. 32.
    Levine MN, Browman GP, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 9: 348–356, 1991PubMedGoogle Scholar
  33. 33.
    Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 33: 441–445, 1984PubMedGoogle Scholar
  34. 34.
    Hery M, Gioanni J, Lalanne CM, Namer M, Courdi A: The DNA labelling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9: 207–211, 1987PubMedGoogle Scholar
  35. 35.
    Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labelling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986PubMedGoogle Scholar
  36. 36.
    Spyratos F, Maudelonede T, Brouillet JP: Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet ii: 1115–1118, 1989Google Scholar
  37. 37.
    Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990PubMedGoogle Scholar
  38. 38.
    Rutqvist LE, Miller AB, Andersson I, Hakama M, Hakulinen T, Sigfusson BF, Tabar L: Reduced breast-cancer mortality with mammography screening. An assessment of currently available data. Int J Cancer 5: 76–84, 1990Google Scholar
  39. 39.
    Tubiana M, Koscielny S: The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys 19: 1117–1120, 1990PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Rodrigo Arriagada
    • 3
  • Lars Erik Rutqvist
    • 1
  • Lambert Skoog
    • 2
  • Hemming Johansson
    • 1
  • Andrew Kramar
    • 3
  1. 1.Oncologic Centre, RadiumhemmetKarolinska HospitalStockholmSweden
  2. 2.Division of Clinical Cytology, Tumor Pathology DepartmentKarolinska HospitalStockholmSweden
  3. 3.Institut Gustave-RoussyVillejuif CedexFrance

Personalised recommendations